İleri evre küçük hücreli dışı akciğer karsinomunda sisplatin-etoposid ile mitomisin-ifosfamid-sisplatin kombinasyonlarının karşılaştırılması
Küçük Resim Yok
Tarih
2006
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Sisplatin-etoposid (CE) ile mitomisin-ifosfamid-sisplatin (MIC) rejimleri küçük hücreli dışı akciğer karsinomu (KHDAK)’nun tedavisinde kullanılan konvansiyonel aktif kombinasyonlardır. Bu çalışmada önceden tedavi almamış evre IIIB ve IV KHDAK hastalarında CE ve MIC tedavilerinde gözlenen yanıt oranlarını, sağkalım, yanıt ve progresyon süreleri ve toksisite durumlarını karşılaştırmak amaçlandı. Retrospektif olarak planlanan bu çalışmada önce Ocak 1997-Aralık 2002 tarihleri arasında ilk basamakta MIC ve CE uygulanan, radikal radyoterapi (RT)’ye uygun olmayan evre IIIB ile evre IV KHDAK olgular belirlendi. Takipleri tam olan olgulardan 45’inin MIC, 167’sinin CE aldığı belirlendi. Kırkbeş MIC olgusuna karşılık 167 CE olgusundan 1997 yılından başlanarak başvuru sırasına göre üç olgudan biri alınacak şekilde rastgele olarak ilk 46 CE olgusu çalışmaya alındı. CE protokolü 21 günlük aralarla, sisplatin 80 mg/m2 (birinci gün), etoposid 100 mg/m2 (bir-üç gün); MIC protokolü mitomisin 6 mg/m2, ifosfamid 3 g/m2, sisplatin 50 mg/m2 (birinci gün) şemasında uygulandı. Veriler ki-kare testi, t-testi, Kaplan Meier sağkalım analizi, Cox regresyon analizi ve logistik regresyon analizi ile değerlendirildi. İstatistiksel analizler için SPSS 11.5 paket programı kullanıldı. Yanıt oranları MIC grubunda %33.3, CE grubunda %34.8, median sağkalım MIC grubunda 28 hafta, CE grubunda 35 hafta olarak bulundu. Median yanıt süresi ve progresyona kadar geçen süre MIC grubunda 23 ve 14 hafta, CE grubunda 32 ve 22 hafta olarak belirlendi. Yanıt oranı, yaşam ve yanıt süresi ile progresyona kadar geçen süre ve ayrıca toksisite oranları açısından iki grup arasında istatistiksel olarak fark bulunmadı. Her iki konvansiyonel kemoterapi (KT) protokolünün benzer etkinlikte olduğu ve güvenle uygulanabileceği sonucuna varılmıştır.
Cisplatin-etoposide (CE) and mitomycin, ifosfamide and cisplatin (MIC) combinations are active conventional regimens in non-small cell lung cancer (NSCLC). In this retrospective study, we compared response rates, survival, duration of response, time-to-progression and toxicity of CE with MIC regimens in treatment of previously untreated patients with stage IIIB and IV NSCLC. We first determined the patients with NSCLC who had stage IIIB or IV and received CE or MIC between January 1997 and December 2002 in our clinic. Out of the eligible patients, 45 received MIC, 167 received CE. In addition 45 MIC patients, we included 46 of the 167 CE patients in the study by selecting one patient of every three patient randomly. In CE protocol, cisplatin 80 mg/m2 on day 1 and etoposide 100 mg/m2 on days 1, 2, 3 (every three weeks); in MIC protocol, mitomycin 6 mg/m2, ifosfamide 3 g/m2, cisplatin 50 mg/m2 on day 1 (every three weeks) were performed. For statistical analysis, chi-square, t-test, Kaplan-Meier survival analysis, Cox regression analysis and logistic regression analysis were used by SPSS 11.5 computer program. The overall response rate was 33.3% in the MIC arm and 34.8% in the CE arm. A respective median survival was 28 weeks for the MIC arm and 35 weeks for the CE arm. Median duration of response and time to progression in each groups were 23 and 14 weeks in MIC arm and 32 and 22 weeks respectively. There was no statistical difference for response rates, duration of survival and response, time top progression and toxicity between the two arms. We consider that the combinations of MIC and CE have similar activity and they can be used confidently in advanced NSCLC.
Cisplatin-etoposide (CE) and mitomycin, ifosfamide and cisplatin (MIC) combinations are active conventional regimens in non-small cell lung cancer (NSCLC). In this retrospective study, we compared response rates, survival, duration of response, time-to-progression and toxicity of CE with MIC regimens in treatment of previously untreated patients with stage IIIB and IV NSCLC. We first determined the patients with NSCLC who had stage IIIB or IV and received CE or MIC between January 1997 and December 2002 in our clinic. Out of the eligible patients, 45 received MIC, 167 received CE. In addition 45 MIC patients, we included 46 of the 167 CE patients in the study by selecting one patient of every three patient randomly. In CE protocol, cisplatin 80 mg/m2 on day 1 and etoposide 100 mg/m2 on days 1, 2, 3 (every three weeks); in MIC protocol, mitomycin 6 mg/m2, ifosfamide 3 g/m2, cisplatin 50 mg/m2 on day 1 (every three weeks) were performed. For statistical analysis, chi-square, t-test, Kaplan-Meier survival analysis, Cox regression analysis and logistic regression analysis were used by SPSS 11.5 computer program. The overall response rate was 33.3% in the MIC arm and 34.8% in the CE arm. A respective median survival was 28 weeks for the MIC arm and 35 weeks for the CE arm. Median duration of response and time to progression in each groups were 23 and 14 weeks in MIC arm and 32 and 22 weeks respectively. There was no statistical difference for response rates, duration of survival and response, time top progression and toxicity between the two arms. We consider that the combinations of MIC and CE have similar activity and they can be used confidently in advanced NSCLC.
Açıklama
Anahtar Kelimeler
Kulak, Burun, Boğaz, Solunum Sistemi
Kaynak
Tüberküloz ve Toraks
WoS Q Değeri
Scopus Q Değeri
Cilt
54
Sayı
2
